| Psoriasis vulgaris
Abrilada vs Wynzora
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Abrilada vs Wynzora with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWynzora has a higher rate of injection site reactions vs Abrilada based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Wynzora but not Abrilada, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Abrilada
Wynzora
At A Glance
SC injection
Every 1-2 weeks
TNF-alpha blocker
Topical
Daily
Vitamin D3 analog + corticosteroid
Indications
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
- Psoriasis vulgaris
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile polyarthritis Weight-based SC dosing every other week for patients 2 years of age and older: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), 40 mg (>=30 kg).
Crohn Disease Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years: weight-based induction then 20 mg every other week (<40 kg) or 40 mg every other week (>=40 kg) starting Day 29.
Ulcerative Colitis 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Week 8 (Day 57).
Psoriasis vulgaris, Uveitis 80 mg SC initial dose, then 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Psoriasis vulgaris Apply to affected areas once daily for up to 8 weeks; do not use more than 100 g per week; discontinue when control is achieved.
Contraindications
—
—
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, accidental injury, nausea, urinary tract infection, sinusitis, hyperlipidemia, flu syndrome, abdominal pain, back pain, hypercholesterolemia, hypertension
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), tuberculosis, malignancies, hepatitis B reactivation, demyelinating disorders, hematologic reactions, heart failure, autoimmunity
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, systemic vasculitis, deep vein thrombosis
Most common (>=1%) Upper respiratory infection, headache, application site irritation
Postmarketing Atrophy, striae, telangiectasias, itching, dryness, hypopigmentation, perioral dermatitis, secondary infection, miliaria, cataracts, glaucoma, increased intraocular pressure
Pharmacology
Adalimumab-afzb is a recombinant human IgG1 monoclonal antibody TNF-alpha blocker that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, reducing inflammation and modulating TNF-induced biological responses including leukocyte migration.
WYNZORA Cream combines calcipotriene, a synthetic vitamin D3 analog, and betamethasone dipropionate, a synthetic corticosteroid; the exact mechanisms of their actions in plaque psoriasis are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Abrilada
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Wynzora
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Abrilada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Wynzora
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Abrilada
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Wynzora
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Abrilada.
No savings programs available for Wynzora.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AbriladaView full Abrilada profile
WynzoraView full Wynzora profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.